Altimmune reported Q2 2026 financial results, updating investors on revenue and profit as the biotech’s financial position comes into focus. Attention now shift

Altimmune reported Q2 2026 financial results, updating investors on revenue and profit as the biotech’s financial position comes into focus. Attention now shifts to execution on its Phase 3 PERFORMA trial in MASH and the company’s pipeline outlook.